[Phase I clinical study of 99mTc-ECD].

Area of Science:

• Nuclear Medicine
• Radiopharmacology
• Neuroimaging

Background:

• Assessing regional cerebral blood flow (rCBF) is crucial for diagnosing various neurological conditions.
• Development of safe and effective radiopharmaceuticals is essential for advanced neuroimaging techniques like SPECT.

Purpose of the Study:

• To evaluate the safety and pharmacokinetic profile of 99mTc-L,L-ethyl cysteinate dimer (99mTc-ECD) in healthy volunteers.
• To determine the suitability of 99mTc-ECD as a SPECT tracer for brain perfusion imaging.

Main Methods:

• Phase I clinical study involving 3 healthy volunteers.
• Administration of 99mTc-ECD and monitoring of vital signs and laboratory parameters.
• Quantification of brain uptake, organ clearance, and radiation dosimetry using SPECT and urine analysis.

Main Results:

• 99mTc-ECD demonstrated a favorable safety profile with no significant adverse effects.
• Rapid brain uptake peaking within 1 minute, followed by sustained concentration.
• Efficient clearance from organs, primarily via renal excretion, with an acceptable radiation dose to the bladder wall.
• High-quality SPECT images were obtained, visualizing brain perfusion.

Conclusions:

• 99mTc-ECD is a safe and well-tolerated radiopharmaceutical.
• Its pharmacokinetic properties support its use for evaluating regional cerebral blood flow.
• 99mTc-ECD shows promise as a valuable agent for SPECT neuroimaging.